Issue

Vol. 66 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

The expression of lncRNA-MALAT1 in breast cancer patients and its influences on prognosis

https://doi.org/10.14715/cmb/2020.66.3.11
Zhenxuan Sun
Department of Breast Surgery, Dalian Central Hospital Affiliated to Dalian Medical University, Dalian 116033, China
Jinquan Liu
Department of Clinical Medicine, Datong University School of Medicine, Shanxi 037009, China
Jintao Liu
Department of Breast Surgery, Dalian Central Hospital Affiliated to Dalian Medical University, Dalian 116033, China

Corresponding Author(s) : Jintao Liu

xu.jin.72@inbox.ru

Cellular and Molecular Biology, Vol. 66 No. 3: Issue 3

Abstract

This study aimed to explore the expression of lncRNA-metastasis associated lung adenocarcinoma transcript 1 (lncRNA-MALAT1) in breast cancer (BC) patients and its influences on the prognosis of the patients. A total of 120 BC patients admitted to our hospital were enrolled as a BC group, of which 58 patients at I/II stage were treated with breast-conserving surgery as an operation group, and the other 62 patients at III/IV stage were treated with neoadjuvant chemotherapy combined with breast-conserving surgery as a combination group. Meantime, 100 healthy people in physical examination during the same period were enrolled as a normal group. The expression of serum lncRNA-MALAT1 in the subjects was determined, and the expression in BC patients and its influences on the patients were analyzed. LncRNA-MALAT1 was over-expressed in patients from the BC group, and the area-under-the-curve (AUC) of it for diagnosing BC was 0.911. After treatment, the expression of lncRNA-MALAT1 in the operation group and the combination group significantly decreased, and the expression of it in patients with good prognosis was greatly lower than that in patients with poor prognosis. The AUC of lncRNA-MALAT1 for predicting poor prognosis was 0.838, and TNM staging, pathological differentiation, tumor diameter, and lncRNA-MALAT1 were independent prognostic factors for poor prognosis of the patients. Furthermore, low expression of lncRNA-MALAT1 was associated with a relatively high 5-year overall survival (OS) of BC patients. The expression of lncRNA-MALAT1 was up-regulated in BC patients, while it was down-regulated in BC patients treated with breast-conserving surgery combined with neo-adjuvant chemotherapy, so lncRNA-MALAT1 can be used as a potential indicator for early diagnosis and prognosis prediction of BC patients.

Keywords

LncRNA-MALAT1 Breast cancer Breast-conserving surgery Neoadjuvant chemotherapy Prognosis.
Sun, Z., Liu, J., & Liu, J. (2020). The expression of lncRNA-MALAT1 in breast cancer patients and its influences on prognosis. Cellular and Molecular Biology, 66(3), 72–78. https://doi.org/10.14715/cmb/2020.66.3.11
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Tao Z, Shi A, Lu C, Song T, Zhang Z and Zhao J: Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys 72: 333-338, 2015.
  2. DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67: 439-448, 2017.
  3. Rojas K and Stuckey A: Breast Cancer Epidemiology and Risk Factors. Clin Obstet Gynecol 59: 651-672, 2016.
  4. Mittal S, Kaur H, Gautam N and Mantha AK: Biosensors for breast cancer diagnosis: A review of bioreceptors, biotransducers and signal amplification strategies. Biosens Bioelectron 88: 217-231, 2017.
  5. Nassar FJ, Nasr R and Talhouk R: MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther 172: 34-49, 2017.
  6. Yang G, Lu X and Yuan L: LncRNA: a link between RNA and cancer. Biochim Biophys Acta 1839: 1097-1109, 2014.
  7. Xiao C, Wu CH and Hu HZ: LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci 20: 2819-2824, 2016.
  8. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and Bai XZ: LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 6: 11652-11663, 2015.
  9. Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Korner C, Polycarpou-Schwarz M, Lavi S, Nevo N, et al: LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med 8: 1052-1064, 2016.
  10. Yoshimoto R, Mayeda A, Yoshida M and Nakagawa S: MALAT1 long non-coding RNA in cancer. Biochim Biophys Acta 1859: 192-199, 2016.
  11. Arun G and Spector DL: MALAT1 long non-coding RNA and breast cancer. RNA Biol 16: 860-863, 2019.
  12. Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian K, Xie Y, Wang S, Xu N, Wang Y and Qi C: miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget 7: 16205-16216, 2016.
  13. Zuo Y, Li Y, Zhou Z, Ma M and Fu K: Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer. Biomed Pharmacother 95: 922-928, 2017.
  14. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F and Committee EG: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 5: v8-30, 2015.
  15. Cserni G, Chmielik E, Cserni B and Tot T: The new TNM-based staging of breast ancer. Virchows Arch 472: 697-703, 2018.
  16. Albornoz CR, Matros E, Lee CN, Hudis CA, Pusic AL, Elkin E, Bach PB, Cordeiro PG and Morrow M: Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer: The Role of Breast Reconstruction. Plast Reconstr Surg 135: 1518-1526, 2015.
  17. Teshome M and Kuerer HM: Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. Eur J Surg Oncol 43: 865-874, 2017.
  18. Narod SA, Iqbal J, Giannakeas V, Sopik V and Sun P: Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol 1: 888-896, 2015.
  19. Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR and Rimm DL: PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 3: 326-332, 2015.
  20. Candelaria RP, Bassett RL, Symmans WF, Ramineni M, Moulder SL, Kuerer HM, Thompson AM and Yang WT: Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. Oncologist 22: 394-401, 2017.
  21. De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, Tchou J and Fisher CS: Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Ann Surg Oncol 23: 3247-3258, 2016.
  22. Puthanveetil P, Chen S, Feng B, Gautam A and Chakrabarti S: Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med 19: 1418-1425, 2015.
  23. Li Z, Xu L, Liu Y, Fu S, Tu J, Hu Y and Xiong Q: LncRNA MALAT1 promotes relapse of breast cancer patients with postoperative fever. Am J Transl Res 10: 3186-3197, 2018.
  24. Miao Y, Fan R, Chen L and Qian H: Clinical Significance of Long Non-coding RNA MALAT1 Expression in Tissue and Serum of Breast Cancer. Ann Clin Lab Sci 46: 418-424, 2016.
  25. Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, Zhang Y, Xing Y and Xi T: MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun 472: 262-269, 2016.
  26. Farquhar C, Marjoribanks J, Basser R and Lethaby A: High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev CD003139, 2005.
  27. Ennour-Idrissi K, Maunsell E and Diorio C: Telomere Length and Breast Cancer Prognosis: A Systematic Review. Cancer Epidemiol Biomarkers Prev 26: 3-10, 2017.
  28. Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, Liu Y and Fu P: The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Ther 9: 5567-5575, 2016.
  29. Carmichael AR: Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 113: 1160-1166, 2006.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1113 Download : 646